Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma.
Fazio
Nicola
N
Grana
Chiara
C
Pelosi
Giuseppe
G
Torrisi
Rosalba
R
Di Meglio
Giovanni
G
Tradati
Nicoletta
N
Lorizzo
Katia
K
De Braud
Filippo
F
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018278:Carcinoma, Neuroendocrine / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D018450:Disease Progression; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008479:Mediastinal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009382:Neoplasms, Unknown Primary / Q000175:diagnosis / Q000188:drug therapy*; D015282:Octreotide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D012074:Remission Induction; D012307:Risk Factors; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D005047:Etoposide; C496730:90Y-octreotide, DOTA-Tyr(3)-; D016190:Carboplatin; D015282:Octreotide